Biomarker discovery in nasopharyngeal carcinoma using proteinchip profiling

Journal of the Hong Kong College of Radiologists

Volumn 11, Issue 2, 2008, Pages 63-68

  Cho, W C S ^a   Ngan, R K C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Biological markers; Mass spectrometry; Nasopharyngeal neoplasms; Protein array analysis; Proteomics

Indexed keywords

BIOLOGICAL MARKER; HISTONE H4; INTER ALPHA TRYPSIN INHIBITOR; SERUM AMYLOID A; THROMBOCYTE FACTOR 4;

CANCER DIAGNOSIS; CANCER RELAPSE; CHINA; HEAVY CHAIN; HONG KONG; HUMAN; HUMAN GENOME PROJECT; NASOPHARYNX CARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SALVAGE THERAPY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 57549090408     PISSN: 10295097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 2007;6:25.
2. Issaq HJ, Veenstra TD. The role of electrophoresis in disease biomarker discovery. Electrophoresis. 2007;28:1980-8.
3. Kanmura S, Uto H, Kusumoto K, et al. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system. Hepatology. 2007;45:948-56.
4. Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikström P. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer. 2007;121:615-20.
5. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol. 2001; 12:65-9.
6. Cho WC, Yip TT, Yip C, et al. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling, Clin Cancer Res. 2004;10:43-52.
7. Vlasova MA, Moshkovskii SA. Molecular interactions of acute phase serum amyloid A: possible involvement in carcinogenesis. Biochemistry (Mosc). 2006;71:1051-9.
8. Yokoi K, Shih LC, Kobayashi R, et al. Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol. 2005;27:1361-9.
9. Combaret V, Bergeron C, Bréjon S, et al. Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett. 2005;228:91-6.
10. Gutfeld O, Prus D, Ackerman Z, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem. 2006;54:63-73.
11. Chan DC, Chen C J, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2007; 14:84-93.
12. Engwegen JY, Mehra N, Haanen JB, et al. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest. 2007;87:161-72.
13. Liu DH, Wang XM, Zhang LJ, et al. Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci. 2007;20:33-40.
14. Cho WC, Yip TT, Ngan RK, et al. Proteinchip array profiling for identification of disease - and chemotherapy - associated biomarkers of nasopharyngeal carcinoma. Clin Chem. 2007;53:241-50.
15. Piñeiro M, Alava MA, González-Ramón N, et al. ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun. 1999;263:224-9.
16. Ngan RK, Lau WH, Yip TT, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann NY Acad Sci. 2001; 945:73-9.
17. Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice? Transfus Med. 2001; 11:403-17.
18. Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol. 2001;13:202-8.
19. Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003;15:15-21.
20. Strieter RM, Belperio JA, Phillips RJ, Keane MP. Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp. 2004;256:173-84.
21. Han ZC, Lu M, Li J, et al. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood. 1997;89:2328-35.
22. Fleischer J, Grage-Griebenow E, Kasper B, et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol. 2002;169:770-7.
23. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-33.
24. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 208;iii:1201-7.
25. Al-Mondhiry H. beta-Thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. Am J Hematol. 1983;14:105-11.
26. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun. 2002;292:587-92.
27. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumor subsets in non-small-cell lung cancer. Lancet. 2003;362:433-9.
28. Henderson NA, Steele RJ. SELDI-TOF proteomic analysis and cancer detection. Surgeon. 2005;3:383-90, 422.
29. Bouamrani A, Ternier J, Ratel D, et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem. 2006;52:2103-6.
30. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc. 2006;137:313-21.
31. Castagna A, Cecconi D, Sennels L, et al. Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res. 2005;4:1917-30.
32. Thulasiraman V, Lin S, Gheorghiu L, et al. Reduction of the concentration difference of proteins in biological liquids using a library of combinatorial ligands. Electrophoresis. 2005;26:3561-71.
33. Chen EI, Hewel J, Felding-Habermann B, Yates JR 3rd. Large scale protein profiling by combination of protein fractionation and multidimensional protein identification technology (MudPIT). Mol Cell Proteomics. 2006;5:53-6.
34. Au JS, Cho WC, Yip TT, et al. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother. 2007;61:570-7.
35. Maurya P, Meleady P, Dowling P, Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 2007;27:1247-55.
36. Borrebaeck CA, Wingren C. High-throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn. 2007;7: 673-86.
37. Shoshan SH, Admon A. Novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark. 2007;3:141-52.